Body composition in children receiving recombinant human growth hormone after renal transplantation  by Feber, Janusz et al.
Body composition in children receiving recombinant human
growth hormone after renal transplantation
JANUSZ FEBER, PIERRE COCHAT, JAN LEBL, HANA KRA´SNICˇANOVA´, JAN SˇTEˇPA´N, LOUIS DAVID,
PIERRE BRAILLON, LAURE BONNET, and JAN JANDA
Unite´ de Ne´phrologie Pe´diatrique, Hoˆpital Edouard Herriot, Lyon, France; and 1st and 2nd Medical Faculty, Charles University, Prague,
Czech Republic
Body composition in children receiving recombinant human
growth hormone after renal transplantation.
Background. Recombinant human growth hormone (rhGH) is
an anabolic hormone promoting protein synthesis in various
tissues. Therefore, changes in body composition may be expected
during rhGH treatment.
Methods. We studied changes in body composition during two
years of rhGH treatment in 21 children after at least one year with
a functioning renal transplant. The mean 6 SD age was 12.9 6 2.5
years at the start of rhGH therapy. A whole body, dual energy
X-ray absorptiometry (DEXA) exam was performed before the
initiation of rhGH therapy (T0), and was repeated at one and two
year intervals after initiation of the therapy (T1 and T2, respec-
tively).
Results. Lean body mass increased by a median of 0.48 SDS
during the first year of treatment (P 5 0.022), and the median
increase during two years of therapy was 0.36 SDS (P 5 0.061).
On the contrary, the median fat body mass decreased by 2.17 SDS
during the T0 to T1 period (P 5 0.04) and by 1.99 SDS during the
T0 to T2 period (P 5 0.055). The index for fat body mass/lean
body mass (FBM/LBM) decreased by a median of 5.3% during T0
to T1 (P , 0.001), however, a slower but still significant decrease
by a median of 4.2% was noted at T2 (P , 0.05). Bone mass
content did not change significantly during rhGH treatment. The
medians in caloric and protein intakes were stable during rhGH
treatment.
Conclusion. A significant increase of lean body mass and a
decrease of fat body mass was noted during rhGH therapy in
children after renal transplantation.
The use of recombinant human growth hormone (rhGH)
in the treatment of growth retarded children with chronic
renal insufficiency has been established as a safe and
efficient therapy both in short [1–3] and long term studies
[4]. rhGH is an anabolic hormone promoting protein
synthesis in various tissues. It also has a lipolytic effect and
an anti-insulin like effect. Therefore, changes in body
composition may be expected during growth hormone
(GH) treatment. However, in other studies, lean body mass
and bone mineral density did not significantly change in
children with chronic renal failure treated by rhGH [5, 6].
The aim of our study was to assess the evolution of body
composition in children treated by rhGH after renal trans-
plantation (Tx). The impact of adequate nutrition for an
optimal response to rhGH was also investigated.
METHODS
Subjects
We studied 21 prepubertal (N 5 6) and pubertal (N 5
15) children after renal transplantation. Primary renal
diseases were congenital in 12 and acquired in 9. The
mean 6 SD age was 12.9 6 2.5 years at the start of rhGH
therapy (Genotonorm, Pharmacia Upjohn, Uppsala, Swe-
den). The dose used was 1 IU/kg body wt/week subcutane-
ously, and the time interval between Tx and the start of
rhGH treatment was 3.74 6 1.96 years (range 1.2 to 7.5
years). All children were treated by prednisone, azathio-
prine and cyclosporine during rhGH treatment. Renal
function was stable at all time periods, as documented by
median serum creatinine level of 78, 84 and 102 mmol/liter
before the start of rhGH therapy, and after one and two
years of rhGH therapy (T0, T1 and T2, respectively).
Children’s height was measured using a Holtain wall-
mounted stadiometer, standard deviation scores (SDS) for
height were used for analysis. Body mass index (BMI) was
calculated by dividing weight in kilograms by the square of
the height in meters, and the SDS for BMI were obtained
from the literature [7].
Absorptiometry
Dual energy X-ray absorptiometry (DEXA) exams were
performed by using Hologic QDR-1000W (Hologic Inc.,
Waltham, MA, USA) and Lunar Corporation (Madison,
WI, USA) devices. Both systems work with a dual energy
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X-ray source (70 to 140 kV), and the thin X-ray pencil
beam obtained after collimation scans in a serpentine x-y
pattern the chosen region of interest or the entire body. A
detector, mechanically connected to the X-ray source and
mounted above the patient, feeds the computer with the
absorption data recorded pixel by pixel for both soft tissue
and bone [8]. When theoretically calculated, the absorption
is directly related to the coefficients of absorption and to
the amount of each component.
Individual scans were analyzed by using the Whole Body
software (version 5.47 for Hologic Inc. and version 1.5e for
Lunar Corp.). The soft tissue analysis in the pediatric mode
assumes a lean tissue hydration factor of 86% [9].
The precision of DEXA measured by coefficient of
variation is less than 2.5% for small infants [8, 10], and it
varies between 0.65% and 2.8% for older children [11].
Radiation dose for a whole body scan is , 5 mrem, which
represents about 1/10 of a normal chest X-ray. The DEXA
exam takes 20 to 35 minutes and requires little cooperation
from the subject. Therefore, this technique has been suc-
cessfully used in pediatric subjects [12], even in small
infants and newborns [8, 10].
In our study, the DEXA exam was performed using
Hologic 1000W (N 5 9) and Lunar (N 5 12) devices before
the initiation of the rhGH therapy (T0) and was repeated at
one and two year intervals. Lean body mass (LBM), fat
body mass (FBM) and whole body bone mineral content
(BMC) were obtained from DEXA exam in grams; abso-
lute values were subsequently transformed to SDS for age,
weight and height [13]. The index FBM/LBM was calcu-
lated for all patients at all time periods.
Nutrition
The intake of calories and proteins was calculated from
a four day-dietary history for the same time periods in nine
children.
Statistics
Results are given as mean 6 SD, median and range.
General linear models procedure for repeated measures
was used for statistical analysis of data repeated in time, a
regression analysis was applied to correlate anthropometry
with DEXA results.
RESULTS
The parameters of body composition before starting and
during rhGH therapy are indicated in Table 1. The chil-
dren’s height (median) increased from 22.18 SDS at T0 to
21.6 SDS at T1 (P , 0.001) and 21.44 SDS at T2 (P ,
0.01).
While the median BMI in SDS was not significantly
different during the rhGH treatment, a wide range of
individual values was noted at all time intervals, from 22
SDS to 15 SDS.
There was a significant increase of LBM by a median of
0.48 SDS during the first year of treatment (P 5 0.022), and
the median increase during two years of therapy was 0.36
SDS (P 5 0.061; Figs. 1 and 2). Similar but less significant
results were obtained for FBM, where the median SDS
decreased by 2.17 SDS during the T0 to T1 period and by
1.99 SDS during the T0 to T2 period (P 5 0.055). Here
again, a wide range of individual values was observed
Fig. 1. Evolution of fat body mass (FBM; dashed line) and lean body
mass (LBM; solid line) during recombinant human growth hormone
(rhGH) treatment.
Table 1. Parameters of body composition before and during two years of rhGH treatment
Parameter Before rhGH 1 year on rhGH 2 years on rhGH
Height (SDS) 22.43 6 1.91 21.97 6 2.04 21.21 6 1.27
22.18 (28.16–1.94) 21.6 (27.62–2.51) 21.44 (23.16–2.28)
BMI (SDS) 0.84 6 1.73 0.83 6 1.48 1.33 6 1.52
0.68 (21.49–4.64) 0.78 (22.35–4.3) 1.17 (20.65–5.16)
Lean body mass (SDS) 20.99 6 1.18 20.52 6 1.00 20.51 6 1.18
20.73 (23.57–0.72) 20.13 (22.87–0.77) 20.28 (23.76–0.73)
Fat body mass (SDS) 6.27 6 8.58 2.78 6 6.33 2.57 6 7.17
4.26 (22.60–29.5) 20.07 (22.38–22.5) 20.05 (22.3–26.5)
FBM/LBM index 0.39 6 0.27 0.30 6 0.21 0.32 6 0.26
0.28 (0.12–1.07) 0.22 (0.11–0.81) 0.22 (0.10–1.06)
Bone mass content (SDS) 20.50 6 1.67 20.58 6 1.54 20.63 6 1.43
20.70 (24.02–3.25) 20.47 (23.82–2.82) 20.27 (24.14–1.21)
Data are presented as mean 6 SD, median and range. Abbreviations are in the Appendix.
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(Table 1 and Fig. 3). Index FBM/LBM decreased signifi-
cantly during the first year by a median of 5.3% (P , 0.001),
the decrease was still significant during the T0 to T2 period
(median change 24.2%, P , 0.05). No significant differ-
ence in changes of LBM and FBM was noted between
prepubertal and pubertal patients. There were no signifi-
cant differences between males and females except for a
greater decrease in FBM during the first year in males
(mean decline, 23.37 6 2.03 SDS) compared to females
(mean decline, 21.34 6 1.58 SDS, P 5 0.049). No corre-
lation was observed between the decline of FBM measured
by DEXA and initial adiposity status expressed as BMI.
No significant change of total body BMC was observed
during one and two years of rhGH treatment.
The intake of calories and proteins (medians) was eval-
uated in nine patients and did not significantly change
during rhGH treatment (47, 37 and 50 kcal/kg/day, and 1.8,
1.5 and 1.6 g/kg/day at T0, T1 and T2, respectively).
DISCUSSION
A positive effect of rhGH on growth in children after
transplantation has been reported in several studies [14–
17]. Height velocity in prepubertal children can be nearly
doubled by rhGH treatment during the first year; however,
the effect of rhGH declines in the second and third year of
treatment [18]. In all studies bone age paralleled chrono-
logical age, therefore preserving the growth potential. In
our study the median SDS for height increased from initial
value of 22.18 to 21.6 SDS by the end of the first year of
rhGH therapy, and smaller improvement was noted by the
end of the second year.
Anabolic and lipolytic effects of rhGH were observed in
children after renal transplantation. rhGH treatment in-
duced a rapid decrease of triceps skinfold thickness as an
indicator of adipose tissue and a slower increase in muscle
mass calculated by midarm muscle circumference [16].
Treatment with rhGH did not result in any significant
changes of lean and fat body mass in chronic renal failure
patients [5]. In another study, muscle mass increased with
no change of fat stores and body mass index [19]. However,
in these studies body composition was assessed using classic
anthropometry or total body potassium without the use of
whole body densitometry. This new precise method has
recently been introduced to assess body composition in
children with renal disease [11]. In a study of nine children
with CRF treated by rhGH, a significant increase of LBM
and decrease of FBM was observed either in relative terms
in the percent of initial values or in SDS for corrected age
[11, 20]. Our study population consisted of previously
reported transplanted children from Lyon, France [11, 20]
and an additional 12 patients from Prague, Czech Republic.
An analysis of the pooled sample showed similar results: a
Fig. 2. Individual changes of lean body mass during rhGH treatment.
Fig. 3. Individual changes of fat body mass during rhGH treatment.
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significant increase of LBM was noted during the first year
of rhGH treatment. Interestingly, the initial SDS values for
LBM were within a broad normal range (23.57 to 0.72)
before rhGH therapy and remained similar during the
study period. On the contrary, FBM exhibits wide interin-
dividual differences throughout the study period. This may
also be the reason for a nonsignificant result at two years of
therapy, but the trend to decrease FBM is obvious, as
documented by the median value of 14.26 SDS at the
beginning and 20.05 SDS at the end of the study. Simul-
taneous changes in both FBM and LBM can be studied
using the FBM/LBM index, which was significantly de-
creased during two years of rhGH therapy.
Effects of rhGH on bone metabolism and bone mineral
density have not been established thus far. No significant
changes in serum calcium, phosphorus, alkaline phospha-
tase and parathyroid hormone concentrations were noted
during rhGH treatment [2, 3, 21–24]. However, the devel-
opment of avascular necrosis of the femoral head was
observed in one patient out of 20 children after four years
of rhGH treatment [4], and two cases of slipped capital
femoral epiphysis occurred in 125 children with CRF
treated by rhGH [3]. At present, there are no data to
suggest that rhGH worsens or induces renal osteodystro-
phy, but children on rhGH therapy should be closely
monitored for bone disease [25]. In CRF children no
changes of bone mineral density were observed during
rhGH treatment [5]. Bone mineral content increased dur-
ing one year of rhGH therapy when taken in absolute
values and percentages of body wt, but no significant
changes were noted in terms of SDS [20]. In our study, no
significant changes of BMC in SDS were observed during
one and two years of rhGH therapy. However, this should
be carefully analyzed since changes in bone mineral density
can occur in renal transplant children without rhGH ther-
apy [26].
Changes in body composition during rhGH treatment
have been described by several authors in renal and non-
renal patients [5, 27–33]. An increase in the fat free mass
was seen as early as six weeks of rhGH therapy and was
correlated to an increase in resting energy expenditure [28].
However, prolongation of the study revealed no significant
changes in body composition and energy expenditure be-
tween 6 and 12 months of treatment [34], so no prediction
of the response to rhGH could be made. A study on
substrate utilization pointed to a protein sparing effect
during the first four months of rhGH treatment with
subsequent normalization by six months of therapy [31].
It is believed that the mechanism of action of rhGH is
mediated through insulin-like growth factors (IGF), pre-
dominantly IGF-I, which are produced in the liver and
other tissues. Several lines of evidence indicate that IGF-I
is nutritionally regulated [35] and may serve as a marker of
nutritional status [36, 37], although serum IGF-I values did
not decrease after reducing the protein intake in adults
with CRF [38]. Protein malnutrition not only decreases the
IGF-I production rate, but also enhances its serum clear-
ance and degradation [36]. In addition, nutrition is an
important regulator of the GH receptor/binding protein
[39], which reflects the GH receptor status. Also, secretion
of GH is greatly influenced by the adiposity status in
children [40], as adiposity altered the amplitude of GH
pulses in pubertal patients and the number of pulses in
prepubertal children [40]. In our patients protein and
caloric intake did not change during the study period.
Hence, nutrition could not influence changes in body
composition seen in our patients.
In conclusion, rhGH treatment results in an increase of
lean body mass and a decrease of fat body mass in children
after renal transplantation. No changes in bone mineral
content were observed during two years of rhGH treat-
ment. Protein and caloric intakes did not vary significantly
during rhGH treatment.
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APPENDIX
Abbreviations used in this article are: BMI, body mass index; DEXA,
dual energy X-ray absorptiometry; FBM, fat body mass; GH, growth
hormone; IGF, insulin-like growth factors; LBM, lean body mass; rhGH,
recombinant human growth hormone; SDS, standard deviation score; Tx,
transplantation.
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